VIGL - Vigil Neuroscience, Inc. Net Margin

VIGL (Vigil Neuroscience, Inc.) - company brandmark

Vigil Neuroscience (VIGL) utilizes a virtual drug development model with outsourced manufacturing, while the GURU.Markets terminal displays a net profit margin chart where the 0.00 mark reflects the latest data. The innovative pipeline, focused on the VG-3927 molecule, faces geopolitical risks that disrupt reagent supplies and complicate the international certification of new therapies.

vigilneuro.com (VIGL) Company Sales Margin: for the period 07/04/2022 - 08/16/2025

Summary analytical data breakdowns for vigilneuro.com (VIGL)

- market value and analyst target forecast:
- market capitalization statistics:
Comprehensive company analysis:Vigil Neuroscience
Flagship merchandise of Vigil Neuroscience

Sales margin reflects the share of net profit from revenue after deducting all operating and tax expenses. For Vigil Neuroscience (VIGL), this parameter demonstrates the efficiency of investments in robotic platforms and AI-driven compound design. By analyzing net profit margin, an investor assesses the ability of automation to reduce drug development costs. This indicator serves as a measure of the business model's actual profitability. Growth in this metric confirms the scalability of the company's technological advantage.

Key competitors

BIIB: Net Sales Margin|Net Margin Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Corp) - Net Sales Margin|AXSM: Net Profit Rate|Net Margin acadia-pharm.com (ACAD)|Net Sales Margin Xenon Pharmaceuticals (XENE)|Net Margin Viking Therapeutics VKTX|Net Profit Rate SUPN|CPRX - Net Margin|Net Margin Denali Therapeutics|HRMY: Net Sales Margin|Biohaven - Net Profit Rate|Return on Sales by Net Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Company Sales Margin|Return on Sales by Net Profit PRAX (Praxis Medicines)|Anavex Corp - Net Return on Sales|Net Margin CeriBell CBLL|Company Sales Margin Prothena Biosciences (PRTA)|ALEC: Return on Sales by Net Profit|ANNX - Net Sales Margin|Omeros Corp. (OMER) - Net Margin|Net Margin Neurogene Inc. (NGNE)|Return on Sales by Net Profit ACIU|Net Margin VYGR|Net Margin Neumora (NMRA)|SCLX - Net Margin|Net Sales Margin TVGN (Tevogen Bio Holdings Inc.)|Net Profit Rate ACOG|Cognition Therapeutics Inc. - Net Sales Margin|IKT - Net Sales Margin|SAVA: Net Sales Margin|Assertio Holdings, Inc. - Net Profit Rate|COYA (Coya) - Net Sales Margin|Net Return on Sales VTGN (Vistagen Therapeutics)|Net Margin Ovid Rx (OVID)|Acumen Pharmaceuticals - Net Return on Sales|Net Margin CervoMed, Inc. CRVO|Net Sales Margin Alterity Therapeutics ATHE|CLNN: Return on Sales by Net Profit|PEPG (pepgen.com) - Net Return on Sales|Jupiter Neurosciences Inc (JUNS) - Net Margin|Relmada Therapeutics - Net Profit Rate|ANVS (Annovis Bio Inc) - Net Sales Margin|GRCE: Net Profit Rate|Net Margin Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Net Profit Rate|Net Margin neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Net Margin|MTVA: Return on Sales by Net Profit|NeurAxis, Inc (NRXS) - Return on Sales by Net Profit|HSDT: Net Sales Margin|PASG - Company Sales Margin|Net Margin Neuphoria Therapeutics, Inc.|Net Margin NERV|Net Sales Margin ATHA|ADXN (Addex Therapeutics Ltd) - Net Profit Rate|Net Margin alzamend.com ALZN|Company Sales Margin Cyclerion Therapeutics (CYCN)|Protagenic - Net Sales Margin|Net Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Net Sales Margin|Avenue Therapeutics Inc. (ATXI) - Net Sales Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Net Sales Margin|Net Sales Margin Cara Therapeutics Inc|Net Margin Chromocell Therapeutics (CHRO)|Company Net Profitability ELYM|Net Margin Intra-Cellular ITCI|LBPH: Net Return on Sales|MRNS - Net Margin|NKGen Biotech, Inc. (NKGN) - Return on Sales by Net Profit|neurobopharma.com (NRBO) - Net Margin|SAGE: Company Net Profitability|Net Margin Synaptogenix, Inc.|Net Margin TRVN|Net Sales Margin WENA|Company Sales Margin Cerevel